Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma

Takuji Torimura(Omuta hospital), Hirohisa Yano(Kurume University), Takato Ueno(Kurume University), Yu Ikezono(Kurume University), Hideki Iwamoto, Osamu Hashimoto(Gifu University), Toru Nakamura(The University of Tokyo), Hiroshi Masuda(Kurume University), Takahiko Sakaue(Kurume University), Fumitaka Wada(Kurume University), Mitsuhiko Abe(Kurume University), Hironori Koga(Kurume University)
Neoplasia
July 1, 2016
10.1016/j.neo.2016.05.001
Cited by 22

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
|Liver International|2020|410